Related Experiment Video
Updated: Nov 21, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy
Xiaonan Zhang1, Tobias Sjöblom1
1Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, SE-75185 Uppsala, Sweden.
Abstract:
Loss of heterozygosity (LOH) is a common genetic event in the development of cancer. In certain tumor types, LOH can affect more than 20% of the genome, entailing loss of allelic variation in thousands of genes. This reduction of heterozygosity creates genetic differences between tumor and normal cells, providing opportunities for development of novel cancer therapies. Here, we review and summarize (1) mutations associated with LOH on chromosomes which have been shown to be promising biomarkers of cancer risk or the prediction of clinical outcomes in certain types of tumors; (2) loci undergoing LOH that can be targeted for development of novel anticancer drugs as well as (3) LOH in tumors provides up-and-coming possibilities to understand the underlying mechanisms of cancer evolution and to discover novel cancer vulnerabilities which are worth a further investigation in the near future.
Insights
Loss of heterozygosity (LOH) is a key genetic event in cancer, impacting thousands of genes. This review explores LOH as a biomarker, therapeutic target, and tool for understanding cancer evolution and vulnerabilities.
Area of Science:
- Genetics
- Oncology
- Genomic Instability
Background:
- Loss of heterozygosity (LOH) is a frequent genetic alteration in cancer development.
- In some cancers, LOH affects over 20% of the genome, leading to substantial loss of genetic variation.
- These genetic differences between tumor and normal cells offer potential for new cancer treatments.
Purpose of the Study:
- To review mutations associated with LOH as cancer biomarkers.
- To identify LOH loci as targets for novel anticancer drug development.
- To explore LOH's role in understanding cancer evolution and discovering new vulnerabilities.
Main Methods:
- Literature review and summarization of existing research on LOH in cancer.
- Analysis of chromosomal regions affected by LOH.
- Identification of genes and loci impacted by LOH events.
Main Results:
- LOH-associated mutations serve as promising biomarkers for cancer risk and clinical outcome prediction.
- Specific LOH loci are viable targets for developing new anticancer therapies.
- LOH provides insights into cancer evolution mechanisms and potential therapeutic vulnerabilities.
Conclusions:
- LOH is a significant factor in cancer genetics with broad implications.
- Further investigation into LOH is crucial for advancing cancer diagnostics and therapeutics.
- Understanding LOH can uncover novel cancer vulnerabilities and treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:39lncRNA - Long Non-coding RNAs
01:27Tumor Immunotherapy